The REG1A antibody is designed to detect REG1A (Regenerating Islet-Derived Protein 1A), a secreted protein belonging to the REG family, which plays roles in cell proliferation, regeneration, and inflammation. REG1A, encoded by the *REG1A* gene, contains a C-type lectin domain and is primarily expressed in pancreatic acinar cells, gastrointestinal tissues, and regenerating islets. It is implicated in pathological conditions such as diabetes, pancreatitis, and cancers, where it may promote tumor growth or tissue repair.
Antibodies against REG1A are valuable tools for research and diagnostics. They enable the detection and quantification of REG1A in biological samples (e.g., serum, tissues) via techniques like ELISA, Western blotting, or immunohistochemistry. In cancer studies, REG1A antibodies help assess its overexpression in gastrointestinal tumors (e.g., colorectal, gastric cancers), correlating with disease progression or prognosis. In diabetes research, they aid in exploring REG1A's role in β-cell regeneration or islet inflammation.
Clinically, REG1A antibodies may contribute to developing biomarker panels for early cancer detection or monitoring therapeutic responses. However, challenges remain in standardizing assays due to REG1A's homology with other REG family members (e.g., REG1B). Further research is needed to clarify its dual roles in tissue repair and disease pathogenesis, potentially unlocking therapeutic strategies targeting REG1A pathways.
(Word count: 247)